Industry Veteran Sal Ventura Joins Hazeltree to Lead Client

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Industry Veteran Sal Ventura Joins Hazeltree to Lead Client Relationship Management

NEW YORK, LONDON AND HONG KONG, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Hazeltree, the leading provider of integrated buy-side treasury management solutions, today expanded its management team by hiring industry veteran Sal Ventura as head of client relationship management. Mr. Ventura brings to Hazeltree more than 25 years of experience in prime brokerage, product development, operations, and client service. As a client service executive, he oversaw the servicing and support of a range of buy-side clients, including hedge fund managers, asset managers, insurance companies and pension funds.

“As regulations continue to impact our industry, we continue to see increased focus on treasury and counterparty management,” said Sameer Shalaby, President and Chief Executive Officer of Hazeltree. “Sal’s industry experience provides him a unique perspective to manage our client relationships as we respond to global market demands.”

Mr. Ventura will be primarily focused on managing client relationships to ensure senior-level sponsorship and connectivity between clients and Hazeltree, prioritizing client requests once they are fully implemented with Hazeltree, and maximizing the value of Hazeltree’s solutions to clients on a continuous basis. 

Mr. Ventura most recently was Managing Director and Global Head of Client Service for JP Morgan’s Custody and Fund Services business.  Prior to that, Ventura was the Global Head of Citigroup’s Investment Banking and Private Banking Operations & Middle Office where he successfully transformed their operations strategy while facing dramatic regulatory change and profitability challenges.  Before joining Citi, Ventura spent 10 years in prime brokerage at Credit Suisse and Lehman Brothers serving hedge fund managers as the Global Head of Prime Broker Client Services responsible for client onboarding and consulting in addition to the day over day client service, business and product development functions. 

“From supporting fund managers for many years, I am fully aware of the significant challenges they face daily, ranging from increased regulations, tough performance, fee pressures, and increased investor demands,” said Sal Ventura, head of client relationship management at Hazeltree. “I joined Hazeltree because it was clear we could make a difference and I am committed to working with our clients to understand their specific needs and harnessing the power of Hazeltree to address them head on.”

Mr. Ventura started his professional career with Price Waterhouse in their Financial Services Industry Practice unit auditing banks, broker dealers, investment companies and alternative managers.  Ventura is a CPA and a graduate of Binghamton University holding a B.S. in Accounting.  

About Hazeltree   Hazeltree is the leading Treasury Management solution provider, serving hedge funds, asset managers, fund administrators, insurance companies and pension funds with powerful, proactive performance enhancement and risk mitigation capabilities that generate operational alpha, reduce a range of risks and streamline operations. Hazeltree’s integrated treasury management solution includes comprehensive cash management, securities financing, collateral management, counterparty management and margin management capabilities. Hazeltree is headquartered in New York with offices in London and Hong Kong. For more information, please visit  www.hazeltree.com . 

Contact: Sameer Shalaby, President & CEO 646.790.7250

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 352

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 377

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading